NasdaqGS:ARVNPharmaceuticals
Arvinas (ARVN) Q1 Loss Of US$0.90 Per Share Challenges Bullish Margin Narratives
Arvinas (ARVN) opened Q1 2026 with revenue of US$15.6 million and a basic EPS loss of US$0.90, alongside trailing twelve month revenue of US$89.4 million and a net loss of US$221.3 million. Over recent quarters the company has seen quarterly revenue move from US$188.8 million in Q1 2025 to US$15.6 million in Q1 2026, while basic EPS has shifted from a profit of US$1.14 per share in Q1 2025 to a loss of US$0.90. This sets up a results season in which investors may focus on how margins evolve...